文献速递泌尿生殖腹部MR

避免不必要活检:MRI风险模型与PI-RADS联合PSA密度策略对临床显著前列腺癌的比较

Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
PubMed 文献 · Radiology · 2021-05-25

该回顾性研究纳入385例未确诊前列腺癌且PI-RADS≥3行多参数MRI和靶向活检的患者,在C1队列(n=242)重新校准并筛选MRI风险模型,在C2队列(n=143)比较其与PI-RADS联合PSA密度策略对活检决策的影响。结果显示,PI-RADS联合PSA密度策略(PI-RADS 3且PSAd<0.1 ng/mL不活检)可安全避免每1000人63例活检且不漏诊csPCa,而MRI风险模型在风险阈值10%无净获益、15%以内净获益仍劣于该策略。

要点

  • PI-RADS 3且PSAd<0.1 ng/mL者可考虑不活检,每1000人避免63例活检且不漏诊csPCa。
  • MRI风险模型在风险阈值10%无净获益,15%以内净获益仍劣于PI-RADS联合PSAd策略。
  • 未在C1重新校准的四个模型中三个校准差且临床无用。

核心结论

  • 对于MRI阳性(PI-RADS≥3)的男性,采用基于PSA密度的策略可安全减少不必要的穿刺活检。
  • 在风险规避场景下,该策略比基于MRI的风险模型能做出更好的活检决策。

研究设计与样本

  • 回顾性研究,纳入385例未确诊前列腺癌且PI-RADS≥3行多参数MRI和MRI靶向活检的患者,时间为2015-2019年。
  • C1队列(n=242,2015-2017)用于重新校准和筛选最佳MRI模型(MRI-ERSPC、van Leeuwen、Radtke、Mehralivand)。
  • C2队列(n=143,2018-2019)用于比较MRI风险模型与PI-RADS联合PSAd策略对活检决策的影响。
  • 参考标准为MRI靶向活检病理,临床显著前列腺癌定义为Gleason评分≥3+4。

诊断标准与关键数值

  • C1队列csPCa患病率为38%(93/242),C2队列为45%(64/143)。
  • 在C2队列中,van Leeuwen模型AUC为0.84(95%CI:0.77,0.9),Mehralivand模型AUC为0.79(95%CI:0.72,0.86)。
  • van Leeuwen和Mehralivand模型在风险阈值10%时无净获益,风险阈值15%以内净获益仍低于PI-RADS联合PSAd策略。
  • PI-RADS联合PSAd策略(PI-RADS 3且PSAd<0.1 ng/mL不活检)每1000人避免63例活检,且未漏诊csPCa。
  • 未在C1重新校准的四个模型中三个(MRI-ERSPC、Radtke、Mehralivand)校准差且在C2临床无用。

临床应用与阅片要点

  • 对于PI-RADS 3且PSAd<0.1 ng/mL的患者,可考虑不进行活检以避免不必要穿刺。
  • 基于MRI的风险模型需在本地队列重新校准后才可能具有临床实用性。
  • 在风险规避场景下,优先采用PI-RADS联合PSAd策略而非MRI风险模型进行活检决策。

局限性

  • 回顾性研究设计。
  • 单中心研究。
  • 样本量有限(总样本385例,C2队列143例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background In validation studies, risk models for clinically significant prostate cancer (csPCa; Gleason score ≥3+4) combining multiparametric MRI and clinical factors have demonstrated poor calibration (over- and underprediction) and limited use in avoiding unnecessary prostate biopsies. Purpose MRI-based risk models following local recalibration were compared with a strategy that combined Prostate Imaging Data and Reporting System (PI-RADS; version 2) and prostate-specific antigen density (PSAd) to assess the potential reduction of unnecessary prostate biopsies. Materials and Methods This retrospective study included 385 patients without prostate cancer diagnosis who underwent multipara-metric MRI (PI-RADS category ≥3) and MRI-targeted biopsy between 2015 and 2019. Recalibration and selection of the best-performing MRI model (MRI-European Randomized Study of Screening for Prostate Cancer [ERSPC], van Leeuwen, Radtke, and Mehralivand models) were undertaken in cohort C1 (n = 242; 2015-2017). The impact on biopsy decisions was compared with an alternative strategy (no biopsy for PI-RADS category 3 plus PSAd < 0.1 ng/mL per milliliter) in cohort C2 (n = 143; 2018-2019). Discrimination, calibration, and clinical utility were assessed by using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis, respectively. Results The prevalence of csPCa was 38% (93 of 242 patients) and 45% (64 of 143 patients) in cohorts C1 and C2, respectively. Decision curve analysis demonstrated the highest net benefit for the van Leeuwen and Mehralivand models in C1. Used for biopsy decisions in C2, van Leeuwen (AUC, 0.84; 95% CI: 0.77, 0.9) and Mehralivand (AUC, 0.79; 95% CI: 0.72, 0.86) enabled no net benefit at a risk threshold of 10%. Up to a risk threshold of 15%, net benefit remained inferior to the PI-RADS plus PSAd strategy, which avoided biopsy in 63 per 1000 men, without missing csPCa. Without prior recalibration in C1, three of four models (MRIERSPC, Radtke, Mehralivand) were poorly calibrated and not clinically useful in C2. Conclusion The number of unnecessary prostate biopsies in men with positive MRI may be safely reduced by using a prostate-specific antigen density-based strategy. In a risk-averse scenario, this strategy enabled better biopsy decisions compared with MRI-based risk models. ©RSNA, 2021 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Deniffel D, Healy GM, Dong X, et al. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. Radiology. 2021. PMID: 34032510. doi:10.1148/radiol.2021204112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。